Immunotherapy for hormone receptor-positive HER2-negative breast cancer

被引：0
作者：
Cardoso, Fatima [1 ]
Hirshfield, Kim M. [2 ]
Kraynyak, Kimberly A. [2 ]
Tryfonidis, Konstantinos [2 ]
Bardia, Aditya [3 ]
机构：
[1] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
[2] Merck & Co Inc, Rahway, NJ USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA USA
来源：
NPJ BREAST CANCER | 2024年 / 10卷 / 01期
关键词：
PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; ADJUVANT ENDOCRINE THERAPY; OPEN-LABEL; HIGH-RISK; NEOADJUVANT CHEMOTHERAPY; LOCALLY RECURRENT; NIVOLUMAB NIVO; TRIAL; PALBOCICLIB;
D O I：
10.1038/s41523-024-00704-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.
引用
收藏
页数：15
相关论文
共 92 条
  • [11] KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
    Cardoso, Fatima
    Bardia, Aditya
    Andre, Fabrice
    Cescon, David W.
    McArthur, Heather L.
    Telli, Melinda L.
    Loi, Sherene
    Cortes, Javier
    Schmid, Peter
    Harbeck, Nadia
    Denkert, Carsten
    Jackisch, Christian
    Jia, Liyi
    Hirshfield, Kim M.
    Karantza, Vassiliki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [12] Cellular immunity in breast cancer patients completing taxane treatment
    Carson, WE
    Shapiro, CL
    Crespin, TR
    Thornton, LM
    Andersen, BL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (10) : 3401 - 3409
  • [13] Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
    Centanni, Maddalena
    Moes, Dirk Jan A. R.
    Troconiz, Inaki F.
    Ciccolini, Joseph
    van Hasselt, J. G. Coen
    [J]. CLINICAL PHARMACOKINETICS, 2019, 58 (07) : 835 - 857
  • [14] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    Cortazar, Patricia
    Zhang, Lijun
    Untch, Michael
    Mehta, Keyur
    Costantino, Joseph P.
    Wolmark, Norman
    Bonnefoi, Herve
    Cameron, David
    Gianni, Luca
    Valagussa, Pinuccia
    Swain, Sandra M.
    Prowell, Tatiana
    Loibl, Sibylle
    Wickerham, D. Lawrence
    Bogaerts, Jan
    Baselga, Jose
    Perou, Charles
    Blumenthal, Gideon
    Blohmer, Jens
    Mamounas, Eleftherios P.
    Bergh, Jonas
    Semiglazov, Vladimir
    Justice, Robert
    Eidtmann, Holger
    Paik, Soonmyung
    Piccart, Martine
    Sridhara, Rajeshwari
    Fasching, Peter A.
    Slaets, Leen
    Tang, Shenghui
    Gerber, Bernd
    Geyer, Charles E., Jr.
    Pazdur, Richard
    Ditsch, Nina
    Rastogi, Priya
    Eiermann, Wolfgang
    von Minckwitz, Gunter
    [J]. LANCET, 2014, 384 (9938) : 164 - 172
  • [15] Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
    Cortes, J.
    Rugo, H. S.
    Cescon, D. W.
    Im, S-A
    Yusof, M. M.
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V
    Pan, W.
    Schmid, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03) : 217 - 226
  • [16] Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9
  • [17] A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2-primary breast cancer: CheckMate 7FL
    Curigliano, G.
    McArthur, H.
    Harbeck, N.
    Pusztai, L.
    Delaloge, S.
    Letrent, K.
    Chen, T.
    Li, B.
    Tatsuoka, K.
    Zardavas, D.
    Loi, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S60 - S61
  • [18] Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis
    Davey, M. G.
    Ryan, E. J.
    Davey, M. S.
    Lowery, A. J.
    Miller, N.
    Kerin, M. J.
    [J]. BRITISH JOURNAL OF SURGERY, 2021, 108 (06) : 622 - 631
  • [19] First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial
    De Caluwe, Alex
    Romano, Emanuela
    Poortmans, Philip
    Gombos, Andrea
    Agostinetto, Elisa
    Marta, Guilherme Nader
    Denis, Zoe
    Drisis, Stylianos
    Vandekerkhove, Christophe
    Desmet, Antoine
    Philippson, Catherine
    Craciun, Ligia
    Veys, Isabelle
    Larsimont, Denis
    Paesmans, Marianne
    Van Gestel, Dirk
    Salgado, Roberto
    Sotiriou, Christos
    Piccart-Gebhart, Martine
    Ignatiadis, Michail
    Buisseret, Laurence
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (12)
  • [20] Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
    Denkert, Carsten
    von Minckwitz, Gunter
    Darb-Esfahani, Silvia
    Lederer, Bianca
    Heppner, Barbara I.
    Weber, Karsten E.
    Budczies, Jan
    Huober, Jens
    Klauschen, Frederick
    Furlanetto, Jenny
    Schmitt, Wolfgang D.
    Blohmer, Jens-Uwe
    Karn, Thomas
    Pfitzner, Berit M.
    Kuemmel, Sherko
    Engels, Knut
    Schneeweiss, Andreas
    Hartmann, Arndt
    Noske, Aurelia
    Fasching, Peter A.
    Jackisch, Christian
    van Mackelenbergh, Marion
    Sinn, Peter
    Schem, Christian
    Hanusch, Claus
    Untch, Michael
    Loibl, Sibylle
    [J]. LANCET ONCOLOGY, 2018, 19 (01) : 40 - 50
12345678910